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Abstract
Background: In acute stage of cerebral infarction, MRI indices (rDWI & rADC) deteriorate during the first 3-7 days
after the ictus and then gradually normalize in approximately 10 days (pseudonormalization time), although the
tissue is already infarcted. Since effective treatments improve these indices significantly and in less than the natural
pseudonormalization time, a combined analysis of these changes provides an opportunity for objective evaluation
on the effectiveness of various treatments for cerebral infarction. Hydroxyl radicals are highly destructive to the
tissue and aggravate cerebral infarction. We treated brainstem infarction patients in acute stage with hydroxyl
radical scavengers (Edaravone and hydrogen) by intravenous administration and evaluated the effects of the
treatment by a serial observation and analysis of these MRI indices. The effects of the treatment were evaluated
and compared in two groups, an Edaravone alone group and a combined group with Edaravone and hydrogen, in
order to assess beneficial effects of addition of hydrogen.
Methods: The patients were divided in Edaravone only group (E group. 26 patients) and combined treatment
group with Edaravone and hydrogen enriched saline (EH group. 8 patients). The extent of the initial hump of rDWI,
the initial dip of rADC and pseudo-normalization time were determined in each patient serially and averages of
these data were compared in these two groups and also with the natural course in the literatures.
Results: The initial hump of rDWI reached 2.0 in the E group which was better than 2.5 of the natural course but
was not as good as 1.5 of the EH group. The initial dip of rADC was 0.6 in the E group which was close to the
natural course but worse than 0.8 of the EH group. Pseudonormalization time of rDWI and rADC was 9 days only
in EH group but longer in other groups. Addition of hydrogen caused no side effects.
Conclusions: Administration of hydroxyl radical scavengers in acute stage of brainstem infarction improved MRI
indices against the natural course. The effects were more obvious and significant in the EH group. These findings
may imply the need for more frequent daily administration of hydroxyl scavenger, or possible additional hydrogen
effects on scavenger mechanisms.
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Clinical care of cerebral infarction patients begins with
visual evaluation of MRI (magnetic resonance image). It
is well known now that the diffusion based MRI
sequences can detect the abnormality within minutes
after the onset of severe ischemia in the brain tissue.
However, the differences in the MRI scan machinery,
display software and filing methods may make the visual
interpretation of the MRI images sometimes inconsis-
tent. The diffusion data are more useful when presented
as a comparison to those in the identical area of the
other side of the brain, because in this way, all the hard-
ware related inconsistency can be removed. The com-
parison utilizes a ratio of the MRI data, particularly the
data capable of determining the degree of water mole-
cule diffusion in the tissue such as DWI (Diffusion
Weighted Image) and ADC (Apparent Diffusion Coeffi-
cient). The ratio is calculated by dividing the data in the
pathological side by those in the normal side and desig-
nated as rDWI (relative DWI) and rADC (relative ADC).
The cells in severely ischemic brain tissue swell due to
accumulation of water and electrolytes in the cells,
immediately after the Na pump fails. The swelling
reduces the extracellular space where the free motion of
water molecules was a major source of the tissue diffu-
sion. Thus, MRI indices (rADC and rDWI) deteriorate
within minutes after the Na pump failure and continue
to get worse for the first 3 to 5 days in the infarcted
brain tissue [1], unless recanalization or restoration of
blood flow occurs [2]. The deterioration of the indices is
characterized by the initial rDWI increase (initial hump)
up to 2.5 or higher and the initial rADC decrease (initial
dip) down to 0.6 or below [3], reaching to a lowest value
on Day3 [4]. Then, both indices gradually return to
close to a normal level or 1.0, despite of the fact that
the tissue is already infarcted (pseudonormalization) in
10 to 11 days (pseudo normalization time) after the
ischemic ictus in the white matter [4]. After the pseudo-
normalization, rADC continues to increase (late hike)
for many months [5,6]. However, recanalization treat-
ment alters this natural course dramatically and the
hump and the dip of diffusion related MRI indices may
not appear at all and the pseudonormalization time
shortens significantly down to 24 hrs or less after the
treatment [7,8], only when the recanalization success-
fully restores the blood flow in the area. Although reca-
nalization treatment such as with tPA (tissue
plasminogen activator) is the most potent treatment of
all for acute cerebral infarction, the treatment needs to
be started within 3 hrs after the onset of the symptoms
and has to satisfy rigid criteria. Therefore, except for
few lucky tPA treated patients, the majority of the acute
cerebral infarct patients are currently treated with
diverse medications, including scavengers of reactive
oxygen species (ROS). The ROS aggravate the ischemic
tissue by a self-propagating chain reaction of depriving
another electron from near-by molecules. In Japan,
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) [9] is
the only medication approved since 2001 for the use in
acute stage of cerebral infarction patients as a scavenger
of hydroxyl radicals and a neuroprotectant [10].
However, in our preliminary study, the treatment of
acute cerebral infarction with Edaravone improved the
initial hump and the initial dip of the MRI indices only
slightly and it shortened the pseudo normalization time
but rather mildly. Edaravone is known to have a rather
short t1/2 beta, or elimination half life of the drug level,
particularly in elderly patients who occupy a majority of
cerebral infarction population. In addition, Cmax, or
maximum drug concentration in the blood, of the Edar-
avone, with currently approved intravenous administra-
tion of 30 mg remains at about 1/10 level of a standard
1-10 micromole concentration used in many in vitro
experiments. In addition, because of possible side effects,
Edaravone may not be given to the patients who have
compromised liver or kidney function and also not
more than twice a day according to the governmental
approval. On the other hand, molecular hydrogen,
which is well known to have potent scavenger actions
against hydroxyl radicals and related harmful oxidation
[11] had no risk of complications in our preliminary
study even on the patients who had already established
kidney or liver disease. Our current study was designed
to supplement possible low and short blood level of
Edaravone with hydrogen for the treatment of acute cer-
ebral infarction. The effects of the supplementing with
hydrogen were evaluated by comparing the results of
the treatment in a group treated with Edaravone only (E
group) and in a combined Edaravone and hydrogen
group (EH group) and also against the natural course
published in the literatures [1-6]. Since subtle neurologi-
cal changes after cerebral infarction during the acute
stage are sometimes difficult to substantiate, a totally
objective method using MRI indices, rADC and rDWI,
was adopted for the evaluation. These indices were cal-
culated at the infarction sites of the patients serially and
averaged and compared daily in the two groups. In addi-
tion, regular neurological evaluation of the patients was
done mainly with NIHSS (NIH stroke score).
Methods
Patients
Consecutive 34 patients who were diagnosed as having
cerebral infarction of BAD type (branch atheromatous
disease) in the brainstem were enrolled in the study.
All of these patients lived in the local area of our hos-
pital and were brought in within 4 to 24 hours after
the onset of the symptoms. The first 26 patients were
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ing 8 patients received hydrogen-rich intravenous fluid
in addition to Edaravone (EH group). For the EH
group of 8 patients, intravenous Edaravone (30 mg
Edaravone Kit) was given at 6 AM and 6 PM as a reg-
ular schedule and hydrogen-rich intravenous solutions
were added at 10 AM and 4 PM. These treatments
lasted for 7 days. Neurological status was recorded
essentially with NIHSS and compared at the time of
admission and discharge from the hospital. The neuro-
logical evaluation was based upon the NIHSS method
and was equally performed in the two groups. Since
the dramatic and substantial improvements in clinical
conditions and MRI indices after recanalization may
overwhelm any effects of other medications, only those
patients who were diagnosed as stroke due to branch
atheromatous disease (BAD), which is a non-recanali-
zation type cerebral infarction, in the brainstem were
recruited. BAD involves perforating arteries particularly
at lateral striate artery (LSA) region or at parapontine
artery (PPA) region and is known as a type of progres-
sive stroke [12] also.
The informed consent in a form approved by the
Nishijima Hospital Ethics Committee was obtained from
all the patients before the treatment or from their legal
guardians when the patients could not sign the consent,
by the time of initiation of the treatment.
Production of hydrogen-rich intravenous fluid
Regular intravenous fluid bags were immersed, without
opening the bag and without adding any alteration on
the bag, in a hydrogen water tank which is capable of
producing hydrogen-rich water up to 1.6 ppm concen-
tration (Miz.Co, Fujisawa, Japan, Patent No.4486157,
Patent Gazette of Japan 2010). The hydrogen concentra-
tion increased in the bag by diffusion through the totally
intact wall of the plastic bag to more than 250 micro-
mole/L and to saturation, depending upon the duration
of the immersion and temperature. A saline bag of 250
ml size (Terumo Co. Tokyo, Japan) and a maltose solu-
tion bag of 200 ml size (Airomu Co. Atsugi, Japan) were
chosen according to the highest diffusibility of the bag
wall we could find.
MRI analysis
MRI signal intensities in DWI and ADC of each infarc-
tion site were observed first and then, serial changes of
these images were compared in the E group and the EH
group. The DWI and ADC signal intensities were also
compared with those in the exactly same area of the
other side of the brain and the ratio was calculated as
rDWI (relative DWI) and rADC (relative ADC).
Averages of these indices were compared in the two
groups and also with the previous publications by using
the data in the literature [3] for a statistical significance.
A special attention was paid for the determination of
abnormal area. Firstly, all of the MRI images of the
patient were reviewed and the largest area of the
a b n o r m a l i t yw a sc h o s e nt ob et h es i t ea n ds i z eo ft h e
lesion for the calculation and the pixel size of the area
were recorded. Then, the area was copied on a transpar-
ent film together with surrounding recognizable struc-
tures as a template, which was used for calculation of
t h er e m a i n d e ro fM R I s .T h i si st op r e p a r e ,i nc a s eo f
size changes of the abnormality or even disappearance
of the abnormality, to calculate the indices exactly in
t h es a m ea r e aa n di nas a m em a n n e r .I fa nA D Cm a p
was not distinct enough by the naked eye, then the
DWI template was used to define the area of abnormal-
ity. The MRI scan was taken on the day of admission
(Day1) and follow-up MRIs were scheduled to be taken
every other day but this could not be accomplished in
every patient when other tests such as patient’s vascular
evaluation or cardiopulmonary function test were
thought to be more urgent.
The study was approved by Nishijima Hospital Ethics
Committee and the production of hydrogen rich IV
fluid as “Hospital Preparation” and its clinical use in
Nishijima Hospital, were conducted upon the advice
from Nishijima Hospital Pharmacists Council and Japa-
nese Welfare-Labour Administration (Tokai-Hokuriku
District Bureau) and Sizuoka Prefectural Administration
(Pharmaceutical Affair, Regulatory Audit Section).
Results
MRI images (DWI and ADC) of infarction areas and
comparison of the images in the E group (treated with
Edaravone only, Figure 1 upper) and the EH group
(treated with a combination of Edaravone and hydrogen,
Figure 1 lower)
The results were firstly evaluated by MRI images (DWI
and ADC) without indices (Figure 1). The DWI images
generally showed increased signal intensity (appeared
with more whiteness) at the infarction sites in both
groups. The ADC images, on the other hand, showed
decreased signal intensity (appeared with more black-
ness) at the lesion sites, which were rather difficult to
s e ea sc o m p a r e dt ot h el e s i o n si nD W Ii m a g e s .T h e s e
signal intensities of the lesions in the E group and the
EH group differed obviously in many cases but in some
cases, the differences were rather subtle when compared
by single images and by the naked eye. However, when
these single images were arranged serially, the differ-
ences between the two groups became more apparent
and the initial hump, the initial dip and the pseudonor-
malization time could be assessed even without the
indices, after getting used to the visual evaluation. In the
E group, the DWI signal intensities increased from Day3
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Figure 1 Serial MRI changes in the upper brain stem lesion slices (1st & 3rd row) and lower brain stem lesion slices (2nd and 4th row)
of DWI (1st & 2nd row) and ADC (3rd & 4
th row) images. upper. Serial MRI of a representative patient in E group on Day 1, 3, 6 (left
to right). The lesion involved two adjacent slices at the upper (1st row) and lower (2nd row) brain stem. The DWI signal intensity (whiteness) of
the upper slice increased on Day3 (presence of the initial hump), but remained almost unchanged on Day 1,3& 6 in the lower slice (2nd row) by
the naked eye. The reduced ADC signal intensity (blackness) of the same lesion was seen even on Day6, particularly in the lower lesion slice (4th
row). lower. Serial MRI of a representative patient in EH group on Day1, 2, 7, 9 (left to right). The lesions also involved two adjacent
slices. The DWI signal intensity of the upper slice (1st row) was seen on Day1 but was invisible on the Day2 &7 (absence of the initial hump).
The initial hump was seen only in the anterior part of the lower lesion slice (2nd row) but not in the posterior-lateral extension of the lesion
towards the cerebellum which had disappeared on Day2 & 7(absence of the initial hump). The ADC signal was clearly darker in the lower
brainstem lesion (4th row) on Day 2 but disappearing on Day7 and became grey colour on Day9 (shortened pseudonormalization time and late
hike, 4th row, right end).
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change was confirmed to be the initial hump by the
rDWI. However, in the EH group, the increase was sig-
nificantly less and in some cases, no increase was seen
at all (absence of the initial hump, Figure 1 lower, 1st
row). In addition, in the E group, the increase lasted
longer than 9 days, which was regarded as the lack of
shortening of the pseudonormalization time (Figure 1
upper, 2nd row) and this was also confirmed by indices.
In the EH group, however, the increase returned to a
normal level by Day 9 in many cases (the shortened
pseudonormalization time, Figure 1 lower, 1st and 2nd
row).
The ADC images when observed in a serial manner
also showed substantial differences between the E group
and the EH group. The degree of reduction of the ADC
signal intensities at the lesion sites was less in EH group
(Figure 1 lower, 3rd and 4th row) and then, increased to
the normal level within Day9, which qualified for the
shortening of the pseudonormalization time. On the
contrary, in the E group, the ADC image at the lesion
site was darker and lasted longer without returning to a
normal level within 9 days (lack of shortening of the
pseudonormalization time, Figure 1 upper, 3rd and 4th
row). The dark ADC intensity at the lesion site became
greyish in colour after 9 days in the EH group and the
whiteness gradually increased further (late hike) after-
wards. In many lesions where the differences were not
obvious by the naked eye, the evaluation by the indices
still demonstrated significant differences. For an exam-
ple, in the upper brain stem lesion of the E group (Fig-
ure 1 upper, 1st row), the initial hump was not too
obvious by the naked eye but the indices (rDWI) were
above the normal level of 1.20 on Day3 and Day5 (1.54
and 1.30, respectively), indicating the presence of the
initial hump. Since ADC images are more difficult to
evaluate by the naked eye, the lack of the pseudonorma-
lization of the lesions such as in the Figure 1 upper, 3rd
and 4th row could only be evaluated by the indices
(rADC), which, at these lesions, had changed from 0.48
to 0.31 to 065 (3rd row) and 0.79 to 0.39 to 0.82 (4th
row) on Day1, Day3 and Day6, respectively. All of these
indices were below the normal level of 0.9 and remained
depressed longer than Day10 and therefore the changes
were regarded as showing the lack of the pseudonorma-
lization (or failure of shortening of the pseudonormali-
zation time). On the other hand, the presence of
shortened pseudonormalization time in the EH group
was shown by the both indices as in Figure 1 lower
lesions. The lesions showed the initial hump of rDWI
(2nd row, 2.03) and the initial dip of rADC (4th row,
0.54) on Day2 but these data improved to 1.14 (rDWI,
as compared to the normal value of less than 1.2) and
to 2.50 (rADC, as compared to the normal value of
more than 0.9), by the Day9 (therefore, the shortened
pseudonormalization time and late hike).
Serial rDWI averages in the E group (treated with
Edaravone only) and in the EH group (treated with a
combination of Edaravone and hydrogen (Figure 2 upper)
Daily averages of rDWI in the E group patients showed
a definite initial hump (above 1.2) between Day4 and
Day8. However, the highest rDWI averages of the E
g r o u pr e m a i n e da t2 . 1l e v e l sa n dd i dn o td e t e r i o r a t ea s
high as 2.5, as in the natural course [3] and the differ-
ence was statistically significant on Day4 (Figure 2
upper). On the other hand, the initial hump was not
seen in the EH group and the difference was significant
(p < 0.05) on the Day5, 8 and 9 (absence of the initial
hump). The rDWI averages of the E group did not fall
below a normal level of 1.2 by Day10 and thus failed to
shorten the pseudonormalization time. However, in the
EH group, the rDWI averages on Day8 and Day9
reached 1.2 or less and thus qualified for the shortening
of the pseudonormalization time. These findings indi-
cate that the treatment in the E group did not abolish
the initial hump and did not shorten the pseudonorma-
lization. However, both conditions were accomplished in
the EH group and in this sense, although the differences
may appear rather minuscule, the results of the treat-
ment in EH group was superior to those of the E group,
when evaluated by the rDWI. The degree of the initial
hump of the E group was significantly less and better
than that of the natural course, however.
Serial rADC averages in the E group (treated with
Edaravone only) and in the EH group (treated with a
combination of Edaravone and hydrogen) (Figure 2 lower)
Daily averages of rADCs in the E group patients showed
the initial dip on the Day4 and Day5. In the EH group,
however, the initial dip appeared to be delayed and
rather short lived on the Day5 and possibly on the Day6
or Day7 but no data available during this period. These
patients were usually scheduled for MRA (MRI angio-
gram) of the cervical carotid artery on the Day3 and
other cardiopulmonary studies on Day6 or Day7 and the
lack of the MRI data on these hospital days made it dif-
ficult to assert the duration of the short lived initial dip.
Definite pseudonormalization of the rADC was not
noted within 10 days in the E group while in the EH
group, the shortening of the pseudonormalization time
was seen on Day9. The rADC of the EH group
increased gradually afterwards (late hike). The difference
of the daily averages between the E group and the EH
group reached a statistical significance on the Day5, 8
and 9. The results of the treatment in EH group were,
therefore, superior to those of E group when evaluated
by the rADC also.
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Edaravone only) and in the EH group (treated with a
combination of Edaravone and hydrogen)
The neurological conditions of the patients recorded
on the Day1 and at the time of discharge from the
hospital were compared. There were 4, 2 and 20
patients, who were regarded as improved, worse and
unchanged, respectively, in the E group. However, all
of the patients in the EH group were regarded as
unchanged, except one patient who had a very high
blood sugar from uncontrolled diabetes and got worse.
The neurological evaluation was based upon NIHSS
and if the score did not show any change, then, the
result of the MMT was added. The difference of the
neurological changes in the two groups was statistically
not significant.
Figure 2 Serial changes in rDWI (upper) and rADC (lower). upper: Daily averages of rDWI in the E group patients showed a mild initial
hump (Day4 to Day8, up to 2.2) but remained less than a natural course (rDWI of 2.5, Huang et al [3]). In the EH group, the initial hump was
not seen (p < 0.05 on the Day 5, 8 and 9). No shortening of the pseudonormalization time was seen in E group (the rDWI average remained
above 1.2 by Day9). In the EH group, the rDWI averages on Day 8 reached the normal level of 1.2 (shortened pseudonormalization time). Lower:
Daily averages of rADCs in the E group patients showed a mild initial dip (Day4 to 7). In the EH group, the initial dip was rather short lived on
Day 5 but no data available on Day6 & 7. No pseudonormalization of the rADC was noted within 9 days in the E group. In the EH group,
however, the shortening was seen on Day 9. Then, the rADC of EH group increased (late hike). The differences of the rADC in the two groups
reached a statistical significance on the Day5, 8 and 9.
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MRI analysis
Since MRI scan is an essential part of the diagnosis of the
cerebral infarction patients, the effects of the infarction
treatment have frequently been evaluated by the MRI scan
also. Previous publications utilized the area of DWI
abnormality as an equivalent to the size of infarction.
However, it is now well known that areas of the DWI
abnormality are consisted of heterogeneous tissues and all
of the area of DWI abnormalities may not progress to
infarction. The increase in the size and density of the DWI
abnormality may not reflect worsening and/or expansion
of the infarction because the DWI data include T2
sequence of the MRI. Therefore, the increase may simply
reflect the increase in water content of the area from vaso-
genic edema or from proliferated primitive and leaky neo-
vasculature and the phenomena are inclusively called “T2
shine through” [13]. Therefore, if the effects of the treat-
ment were analyzed only by the increase or decrease of
the size and density of the DWI abnormality, the analysis
may falsely conclude the treatment to be ineffective or
effective, respectively. The ADC is not influenced by the
T2 change and more valuable than DWI. However, since
the ischemic tissue abnormality reduces the ADC data and
this makes the area of the ADC abnormality very difficult
to discern from the surrounding tissue. Therefore, the
analysis of the effects of the treatment based upon the size
o ft h eD W I / A D Ca b n o r m a l i t yw a st h o u g h tt ob ei n a p -
propriate and we adopted the current technique. The
technique is to calculate the average number of DWI/
ADC raw data within the identical area of the brain within
the recorded pixel size in all the MRI images obtained
during the hospitalization by using a specific template
made for each patient. This appeared to have accom-
plished the calculation in exactly same area of the same
size in a consistent manner. This technique has been uti-
lized in pharmacological evaluation of medications in the
ischemic brain in the past but mainly in the animal experi-
ments, probably due to difficulty in obtaining frequent
MRI scans in clinical settings.
Our study included only brainstem infarction cases
because of ease of defining the perimeter of the lesion
for the calculation. The brainstem infarctions are usually
round or oval in shape and small and very discrete from
the surrounding tissue. In addition, the tissue is mainly
consisted of white matter and devoid of CSF space. The
MRI indices are influenced by the heterogeneity of the
tissue [4] and particularly by the presence of CSF space
in the tissue as in the cerebral cortical lesions.
Neurological evaluation of brainstem infarction patients
with NIHSS
All of the patients in the EH group were regarded as
neurologically unchanged except one patient after the
combined treatment with Edaravone and hydrogen,
based upon the NIHSS. However, all of these patients in
the EH group except one were satisfied with significant
improvement of their preadmission symptoms by the
time of discharge from the hospital. NIHSS is the most
reliable and most accepted neurological scoring system
for stroke patients which is calculated and recorded
after performing well described and rather simple neu-
rological examinations. However, these examinations are
heavily weighted for the evaluation of anterior circula-
tion stroke. Major symptoms of our brainstem stroke
patients were due to posterior circulation abnormality
and included dizzy sensation, vertigo without nystagmus,
vague and subjective paresthesia of one side of the body
with normal touch sensation, difficulty in walking from
some swaying and staggering sensation but with normal
knee to heel tests, normal diadochokinesis and normal
muscle strength, in addition to some sensation of swal-
lowing difficulty with normal gag reflex etc. None of
these symptoms are calculable by NIHSS and therefore,
the patient’s satisfaction in the EH group was not
reflected as improvement in the NIHSS.
Effects of hydroxyl radical scavengers, Edaravone and
hydrogen on cerebral infarction
The beneficial effects of Edaravone in the treatment of
cerebral infarction have been well established [14]. Edar-
avone is known for its unique property with both water
and lipid solubility and has potent scavenger action
against hydroxyl and peroxynitrite radicals and ROS
[15]. It acts also in reducing the brain edema of the
ischemic brain tissue by protecting endothelial cells
from ROS and by keeping integrity of the blood brain
barrier and also by reducing the inflammatory responses
in the ischemic area of the brain [16]. Initially, Edara-
vone was thought to be a simple quencher of the radi-
cals but later many neuroprotective properties were
found [17,18], and effectiveness in many organs and
many disease conditions are added [19,20]. Currently, it
is recognized as a most effective scavenger of radicals
and also neuroprotective agents in Japanese neurosurgi-
cal community but additional clinical studies were dis-
cussed in the U.S.A [21].
Hydrogen is also known as a potent scavenger of the
hydroxyl and peroxynitrite radicals and does not affect
NO production which is advantageous to the ischemic
brain tissue. The investigational and clinical interests
have been promulgated recently by epochal articles [11]
and a review [22]. Direct actions of hydrogen on extra-
cellular and intracellular hydroxyl radical provide pro-
tection of mitochondria and nuclear DNA but hydrogen
does not harm other cellular elements which relate to
signal transduction. When hydrogen was given during
r e p e r f u s i o ni na na n i m a li s c h e m i cb r a i nm o d e l ,i t
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although only when hydrogen was given during the
reperfusion but not during the ischemic period. However,
these effects were actually better than those of Edaravone
and FK506 combination [11]. Since FK506 alone is
known to decrease the ischemic brain size, it is remark-
able that hydrogen superseded the effects of the combi-
nation. In addition, hydrogen demonstrated extended
effectiveness in many other organs and in various situa-
tions such as in diabetes[23], intestinal grafts[24], tumor
growth inhibition [25], allograft nephropathy[26], cardiac
ischemia/reperfusion[27], sepsis [28], liver injury [29],
haemodialysis[30], spinal cord injury[31], an animal
model of Parkinson’s disease[32] and Alzheimer’s disease
[33], in addition to health promotion [34]. Therefore,
there is nothing to indicate that hydrogen is inferior to
Edaravone for the treatment of cerebral infarction and it
is quite possible that a single use of hydrogen is as effec-
tive as Edaravone treatment and probably much safer.
However, it would be an unethical conduct until larger
controlled clinical studies accumulate more evidences,
because of limitations of our study. However, if the
advantages in the EH group of current study were sub-
stantiated in the future studies, the advantages may be
due to the increased frequency of administration of the
radical scavengers as was in EH group (4 times per day
vs. 2 times per day), and/or direct hydrogen effects on
the inflammatory cells, chemokines and growth and anti-
apoptoic factors and/or a direct neutralizing action on
the residual radical substances of intermediate Edaravone
metabolites in ischemic and hypoxic brain tissue. Edara-
vone putatively provides electrons and becomes a radical
by itself until it reacts with oxygen and then changes,
through Edaravone peroxyl radical, to a non-radical
material, 2-oxo-3-(phenylhydrazono)-butanoic acid
(OPB) [35] which may accumulate in the brain even-
tually. Hydrogen may have interacted with those inter-
mediate radical products favourably and provided better
MRI changes in our study. At the beginning of this study,
our concerns included the government approved and
recommended Edaravone dose (60 mg/day for 2 weeks =
840 mg) and subsequent blood level dynamics. It is inter-
esting that a currently on going Phase 2 study in Europe
increased the Edaravone doses from 840 mg to 1000 mg
and 2000 mg [21]. The results of the study may solve
some of our concerns.
The limitations of our study include a non-controlled
way of patient selection, inclusion of rather small num-
ber of the patients particularly in the combined group,
use of current NIHSS for neurological evaluation for the
brainstem infarction, lack of long term follow-up etc.
We are organizing a new study to improve these limita-
tions currently.
Conclusions
Administration of hydroxyl radical scavengers in acute
stage of brainstem infarction improved MRI indices
(rDWI, rADC) against the natural course. The favour-
able effects were more obvious and significant in the EH
group (a combined group of Edaravone and hydrogen)
as compared to the E group (Edaravone alone group).
These findings may imply the need for more frequent
daily administration of hydroxyl radical scavenger, or
possible presence of additional hydrogen effects on sca-
venger mechanisms.
Acknowledgements
The authors would like to thank Miz Company for technical assistance for
setting up the hydrogen water tank and initial measurement of hydrogen
concentration in the intravenous fluid bag.
Author details
1Department of Neurosurgery, Nishijima Hospital, Oooka, Numazu City,
Sizuoka, 410-0022, Japan.
2Department of Neurosurgery, National Defence
Medical College, Tokorozawa City, Saitama,359-8513, Japan.
Authors’ contributions
The authors equally contributed to the production of this article and have
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests and were not
compensated at all by any pharmaceutical and biotechnology company or
any other companies to contribute this article to the peer-reviewed scientific
literature.
Received: 16 March 2011 Accepted: 7 June 2011 Published: 7 June 2011
References
1. Yang Q, Brian M, Tress BM, Barber PA, Desmond PM, Darby DG, Gerraty RP,
Li T, Davis SM: Study of apparent diffusion coefficient and anisotropy in
patients with Acute Stroke. Stroke 1999, 30:2382-2390.
2. Schwamm LH, Koroshetz WJ, Sorensen GA, Wang B, Copen WA, Rordorf G,
Buonanno FS, Schaefer PW, Gonzalez GR: Serial Diffusion-and
Hemodynamic-Weighted Magnetic Resonance Imaging. Stroke 1998,
29:2268-2276.
3. Huang IJ, Chen CY, Chung HW, Chang DC, Lee CC, Chin SC, Liou M: Time
Course of Cerebral Infarction in the Middle Cerebral Arterial Territory:
Deep Watershed versus Territorial Subtypes on Diffusion-weighted MR
Images. Radiology 2001, 221:35-42.
4. Fiebach JB, Schellinger JO, Sartor HW: Serial analysis of the apparent
diffusion coefficient time course in human stroke. Neuroradiology 2002,
44:294-298.
5. Liu S, Karonen JO, Liu Y, Vanninen Ft, Partanen K, Cinbnen MK, Vainio P,
Aronen HJ: Serial Measurements of the Apparent Diffusion Coefficient in
Human Stroke on Five Time Points over Three Months. Proc Intl Sot Mag
Reson Med 2000, 8:1203.
6. Huang L, Wong XH, Li G: The application of DWI and ADC map in
cerebral infarction. Proc Intl Soc Mag Reson Med 2001, 9:1446.
7. Marks MP, Tong DC, Beaulieu C, Albers GW, deCrespigny A, Moseley MR:
Evaluation of early reperfusion and i.v. tPA therapy using diffusion-and
perfusion-weighted MRI. Neurology 1999, 52:1792-1798.
8. Schaefer POW, Hassankhani A, Putman C, Sorensen GA, Schwamm L,
Koroshez W, Gonzalez GR: Characterization and evolution of diffusion
MNRE imaging abnormalities in Stroke patients undergoing intra-arterial
thrombolysis. ANJR 2004, 25:951-957.
9. Tanaka M: Pharmacological and clinical profile of the free radical
scavenger edaravone as a neuroprotective agent. Folia Pharmacol Jpn
2002, 119:301-308.
Ono et al. Medical Gas Research 2011, 1:12
http://www.medicalgasresearch.com/content/1/1/12
Page 8 of 910. Kageyama M, Toriyama S, Tsubosita A, Muraki S, Yamada T, Ishibashi A: A
post-marketing drug use survey of a neuroprotecive drug Radicut
injection 30 mg(non-proprietary name: edaravone) for acute ischemic
stroke. J New Rem Clin 2009, 58:1212-1226.
11. Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K,
Katsura K, Katayama Y, Asoh S, Ohta S: Hydrogen acts as a therapeutic
antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med
2007, 13:688-694.
12. Takagi M: Concept of branch atheromatous disease. Neurol Med 2008,
69:542-549.
13. Burdett JH, Elster AD, Ricci PE: Acute Cerebral Infarction: Quantification of
Spin-Density and T2 Shine-through Phenomena on Diffusion-weighted
MR Images. Radiology 1999, 212:333-339.
14. Edaravone Acute Infarction Study Group: Effect of a novel free radical
scavenger, edaravone (MCI-186), on acute brain infarction. Randomized,
placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis
2003, 15:222-229.
15. Yamamoto Y, Kuwahara T, Watanabe K, Watanabe K: Antioxidant activity of
3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Report 1996, 2:333-338.
16. Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, Urabe T:
Edaravone reduces early accumulation of oxidative products and
sequential inflammatory responses after transient focal ischemia in mice
brain. Stroke 2005, 36:2220-2225.
17. Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito KI: Effects of a novel
free radical scavenger, MCl-186, on ischemic brain damage in the rat
distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 1997,
281:921-927.
18. Yoshida H, Metoki N, Ishikawa A, Imaizumi T, Matsumiya T, Tanji K, Ota K,
Ohyama C, Satoh K: Edaravone improves the expression of nerve growth
factor in human astrocytes subjected to hypoxia/reoxygenation. Neurosci
Res 2010, 66:284-289.
19. Zhang W, Sato K, Hayashi T, Omori N, Nagano I, Kato S, Horiuchi S, Abe K:
Extension of ischemic therapeutic time window by a free radical
scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res 2004,
26:342-348.
20. Watanabe T, Tahara M, Todo S: The Novel Antioxidant Edaravone: From
Bench to Bedside. Cardiovascular Therapeutics 2008, 26:101-114.
21. Lapchak PA: A critical assessment of edaravone acute ischemic stroke
efficacy trials: is edaravone an effective neuroprotective therapy? Expert
Opinion on Pharmacotherapy 2010, 11:1753-1763.
22. Nakao A, Sugimoto R, Billiar TR, McCurry KR: Therapeutic antioxidant
medical gas. J Clin Biochem Nutr 2009, 44:1-13.
23. Kajiyama S, Hasegawa G, Asano M, Hosoda H, Fukui M, Nsksmura N,
Kitawaki J, Imai S, Nakano K, Ohta M, Adachi T, Obayashi H, Yoshikawa T:
Supplementation of hydrogen-rich water improves lipid andd glucose
metabolism in patients with type 2 diabetes or impaired glucose
tolerance. Nur Res 2008, 28:137-143.
24. Buchholz BM, Kaczorowski DJ, Sugimoto R, Yang R, Wang Y, Billiar TR,
McCurry KR, Bauer AJ, Nakao A: Hydrogen inhalation ameliorates
oxidative stress in transplantation induced intestinal graft injury. Am I
transplant 2008, 8:2015-2024.
25. Saitoh Y, Okayasu H, Xiao L, Harata Y, Miwa N: Neutral pH hydrogen-
enriched electrolyzed water achieves tumor-preferential clonal growth
inhibition over normal cells and tumor invasion inhibition concurrently
with intracellular oxidant repression. Oncol Res 2008, 17:247-255.
26. Cardinal JS, Zhan J, Wang Y, Sugimoto R, Tsung A, McCurry KR, Billar R,
Nakao A: Oral administration of hydrogen water prevents chronic
allograft nephropathy in rat renal transplantation. Kidney Int 2010,
77:101-109.
27. Nakao A, Kaczorowski DJ, Wang Y, Cardinal JS, Buchholz BM, Sugimoto R,
Tobita K, Lee S, Toyoda Y, Billar TR, McCurry KR: Amelioration of rat cardiac
cold ischemia/reperfusion injury with inhaled hydrogen or carbon
monoxide, or both. J Heart Lung Transplant 2010, 29:544-553.
28. Xie K, Yu Y, Pei Y, Hou L, Chen S, Xiong L, Wang G: Protective effects of
hydrogen gas on murine polymicrobial sepsis via reducing oxidative
stress and HMGB1 release. Shock 2010, 34:90-97.
29. Liu Q, Shen WF, Sun HY, Fan DF, Nakao A, Cai JM, Yan G, Zhou WP,
Shen RX, Yang JM, Sun XJ: Hydrogen-rich saline protects against liver
injury in rats with obstructive jaundice. Liver Int 2010, 30:958-968.
30. Nakayama M, Nakao H, Hamada H, Itami N, Nakazawa R, Ito S: A novel
bioactive hemodialysis system using dissolved dihydrogen(H2) produced
by water electrolysis: a clinical trial. Nephrol Dial Transplant 2010,
25:3026-3033.
31. Chen CW, Chen QB, Mao YF, Xu SM, Xia CY, Shi XY, Zang ZH, Yuan HB,
Sun XJ: Hydrogen-rich saline protects against spinal cord injury in rats.
Neurochem Res 2010, 35:1111-1118.
32. Fujita K, Seike T, Yutsudo N, Ohno M, Yamada H, Yamaguchi H, Sakumi K,
Yamakawa Y, Kido M, Takaki A, Katafuchi T, Tanaka Y, Nakabeppu y,
Noda M: Hydrogen in drinking water reduces dopaminergic neuronal
loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of
Parkinson disease. PloS One 2009, 30:1-10, e7247.
33. Li J, Wang C, Zhang JH, Cai JM, Cao YP, Sun XJ: Hydrogen-rich saline
improves memory function in a rat model of amyloid-beta-induced
Alzheimer’s disease by reduction of oxidative stress. Brain Res 2010,
1328:152-161.
34. Nakao A, Toyoda Y, Sharma P, Evans M, Guthrie N: Effectiveness of
Hydrogen Rich Water on Antioxidant Status of Subjects with Potential
Metabolic Syndrome–An Open Label Pilot Study. J Clin Biochem Nutr
2010, 46:140-149.
35. Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M: Edaravone (3-methyl-1-
phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment
of cardiovascular disease. Recent Patents on Cardiovascular Drug Discovery
2006, 1:85-93.
doi:10.1186/2045-9912-1-12
Cite this article as: Ono et al.: Improved brain MRI indices in the acute
brain stem infarct sites treated with hydroxyl radical scavengers,
Edaravone and hydrogen, as compared to Edaravone alone. A non-
controlled study. Medical Gas Research 2011 1:12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ono et al. Medical Gas Research 2011, 1:12
http://www.medicalgasresearch.com/content/1/1/12
Page 9 of 9